Vaccines incorporating a mutated form of the HCMV immediate early protein (HCMV-IE1mut) when combined with tumor-associated antigens such as Fibrinogen-like protein 2 (FGL2) have demonstrated synergistic effects in preclinical models. The gene discussed is FGL2; the disease is neoplasm.